AstraZeneca PLC - American Depositary Shares (NY:AZN)

184.38 UNCHANGED

Delayed Quote Updated: 7:00 PM EST, Nov 12, 2026 Add to My Watchlist

Price and Volume

Volume	3,999
Open	184.38
Bid (Size)	184.41 (100)
Ask (Size)	184.52 (900)
Prev. Close	184.38
Today's Range	184.38 - 184.38
52wk Range	153.41 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.50%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Where Will IonQ Stock Be in 5 Years? ↗

November 12, 2026

IonQ is beating the odds, but a lot can happen between now and 2031.

Via The Motley Fool

AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US

November 10, 2026

From AstraZeneca

Via Business Wire

Performance

52-Week Range 13.3% below 52-week high

184.38

153.4152W Low 212.7152W High

1 Week 3.0% below 1-week high

181.201W Low 190.171W High

AstraZeneca PLC - American Depositary Shares (AZN) traded between $153.41 and $212.71 over the past 52 weeks and last traded at $184.38, 13.3% below its 52-week high. Over the past week it ranged between $181.20 and $190.17.

Past 12 Months

-1.1%

+18.3%

+17.3%

-0.3%

-2.1%

1W -$2.05

1M +$28.56

3M +$27.14

6M -$0.58

YTD -$4.03

1Y -$4.03

AZN was -2.1% over the past year, -0.3% over six months, -2.1% year to date, -1.1% in the last week.

12 Months vs Market

AZN

-2.1%

DIA

+8.2%

SPY

+10.8%

QQQ

+10.8%

IWM

+14.3%

Over the past 12 months AZN returned -2.1% versus DIA (Dow) +8.2%, SPY (S&P 500) +10.8%, QQQ (Nasdaq 100) +10.8% and IWM (Russell 2000) +14.3%.

Volume & Liquidity 0.00× 3-mo avg

Today 3,999 3-mo avg 3.1M

2.0M

3.2M

3.1M

2.9M

YTD

2.7M

AZN most recently traded 3,999 shares against a 3-month average daily volume of 3.1M.

More News

Gabelli Releases Agenda for 8th Annual Healthcare Symposium

November 09, 2026

From Gabelli Funds

Via GlobeNewswire

AstraZeneca (NYSE:AZN) Stands Out for Dividend Quality and Sustainable Payout ↗

November 05, 2026

Via Chartmill

AstraZeneca: 3 Key Takeaways for Long-Term Investors ↗

November 01, 2026

Via The Motley Fool

AstraZeneca (AZN) Q3 2026 Earnings Call Transcript ↗

October 31, 2026

Via The Motley Fool

AstraZeneca Q3 Earnings Call Highlights ↗

October 30, 2026

Via MarketBeat

AstraZeneca results: 9M and Q3 2026

October 30, 2026

From AstraZeneca

Via Business Wire

AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing

October 28, 2026

From AstraZeneca

Via Business Wire

AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update ↗

October 26, 2026

Via MarketBeat

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

October 25, 2026

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

October 25, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

October 24, 2026

From AstraZeneca

Via Business Wire

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

October 24, 2026

From AstraZeneca

Via Business Wire

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

October 22, 2026

From AstraZeneca

Via Business Wire

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

Via The Motley Fool

TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week

October 20, 2026

From AstraZeneca

Via Business Wire

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

October 19, 2026

From AstraZeneca

Via Business Wire

AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint ↗

October 12, 2026

Via MarketBeat

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

Via The Motley Fool

2 Growth Stocks to Buy in October ↗

October 08, 2026

Via The Motley Fool

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

October 05, 2026

From AstraZeneca

Via Business Wire

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Via The Motley Fool

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

September 25, 2026

From AstraZeneca

Via Business Wire

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Via The Motley Fool

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 184.38

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 11/12/26 07:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.